7

Welcome to the Brand page for “7”, which is offered here for The mark consists of the stylized design of a number 7 comprised of an elongated upper triangle in dark green and an elongated lower triangle in light green. the elongated upper triangle has a rounded point at its upper right, and its lower side is curved inwardly where it interfaces with the lower elongated triangle, which has a rounded point at its upper right.;pharmaceutical preparations and substances for the treatment of diseases, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer; genetically modified cells, genome editing reagents and biological preparations, viral vectors, all for the treatment of diseases, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer;seven;the color(s) light green and dark green is/are claimed as a feature of the mark.;pharmaceutical research and development;.

Its status is currently believed to be active. Its class is unavailable. “7” is believed to be currently owned by “2seventy bio, Inc.”

Owner:
2SEVENTY BIO, INC.
Owner Details
Description:
The mark consists of the stylized design of a number 7 comprised of an elongated upper triangle in dark green and an elongated lower triangle in light green. The elongated upper triangle has a rounded point at its upper right, and its lower side is curved inwardly where it interfaces with the lower elongated triangle, which has a rounded point at its upper right.;Pharmaceutical preparations and substances for the treatment of diseases, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer; genetically modified cells, genome editing reagents and biological preparations, viral vectors, all for the treatment of diseases, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer;SEVEN;The color(s) light green and dark green is/are claimed as a feature of the mark.;Pharmaceutical research and development;
Categories: